Myasthenia gravis (MG) is an autoimmune neurological disorder characterized by defective
transmission at the neuromuscular junction. The incidence of the disease is 4.1 to 30 cases …

The neuromuscular junction nicotinic acetylcholine receptor (AChR), a pentameric
membrane glycoprotein, is the autoantigen involved in the autoimmune disease myasthenia …

An analysis of the known cytotoxic and helper T cell epitopes has revealed similarity within
their primary sequences. These similar motifs, characteristic of the known determinants …

Acetylcholine receptor (AChR) binding and AChR modulating antibodies were found with
approximately the same frequency (86%) in 349 patients with myasthenia gravis (MG) …

Recently, several novel, potentially lethal and treatment‐responsive syndromes that affect
hippocampal and cortical function have been shown to be associated with auto‐antibodies …

Experimental autoimmune myasthenia gravis (EAMG), a model for human myasthenia (MG),
is routinely induced in susceptible rat strains by a single immunization with Torpedo …

Objective We developed an assay that detects autoantibodies against the main
immunogenic region (MIR) located at the extracellular end of the nicotinic acetylcholine …

RA is characterized by massive proliferation of synovial tissue, accompanying infiltration of
the tissue with CD4+ T lymphocytes, and a genetic linkage to the MHC antigen HLA-DR4 …

Myasthenia gravis (MG) and its animal model experimental autoimmune myasthenia gravis
(EAMG) are caused by autoantibodies against nicotinic acetylcholine receptor (AChR) in …

CD4+ T cells have been shown to be crucial in the development of experimental
autoimmune myasthenia gravis (EAMG). The role of CD8+ T cells in EAMG is less well …